Pharmaceuticals

Allogeneic T Cell Therapies Industry Anticipated to Expand at 9.4% CAGR During the Forecast Period

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Allogeneic T Cell Therapies Market By 2029?

The size of the allogeneic t cell therapies market has demonstrated substantial growth in recent years. This market is projected to expand from $1.16 billion in 2024 to reach $1.26 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 9.0%. Historically, this growth can be ascribed to factors such as regulatory approvals, a rising incidence of cancer, an increase in clinical trials, support from government funding, and an expanding elderly demographic.

The allogeneic t cell therapies market is projected to experience substantial expansion over the coming years, reaching $1.81 billion by 2029, driven by a compound annual growth rate (CAGR) of 9.4%. This anticipated expansion throughout the forecast period stems from factors such as a broadening range of indications, an increasing need for cell-based immunotherapies, heightened understanding of advanced therapeutic options, greater spending on healthcare, and favorable reimbursement frameworks. Key developments anticipated during this timeframe encompass progress in research and development efforts, the adoption of personalized medicine, the availability of off-the-shelf therapies, wider global market penetration, the formation of strategic collaborations, and changes in the regulatory environment.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18952&type=smp

Which Industry Drivers Are Expected To Accelerate The Allogeneic T Cell Therapies Market From 2025 To 2029?

The rising incidence of cancer is anticipated to drive the expansion of the allogeneic T cell therapies market in the future. Cancer encompasses a range of illnesses defined by the unchecked proliferation and dissemination of atypical cells within the body. The increase in cancer occurrences can be attributed to several factors including extended lifespans, evolving lifestyles, environmental interactions, infections, inherited predispositions, and shifts in reproductive behaviors, all of which jointly lead to a greater prevalence and diagnosis of the condition. In cancer treatment, allogeneic T cell therapies involve introducing genetically modified donor T cells, designed to identify particular tumor antigens, into patients to target and eliminate malignant cells. As an illustration, in May 2024, data from the National Cancer Institute, a US-based government agency, indicated approximately 18.1 million cancer survivors resided in the United States. This number is forecast to climb to 22.5 million by 2032. Furthermore, by 2040, annual new cancer diagnoses are projected to reach 29.9 million, and cancer-related fatalities are estimated to grow to 15.3 million. Consequently, the growing prevalence of cancer fuels the allogeneic T cell therapies market.

What Are The Emerging Segments Gaining Attention In The Allogeneic T Cell Therapies Market?

The allogeneic t cell therapies market covered in this report is segmented –

1) By Product Type: Chimeric Antigen Receptor (CAR) T Cell Therapies, T Cell Receptor (TCR) Therapies, Other Product Types

2) By Antigen Type: CD 19, CD 20, Egfrvlll, GD2, CD22, CD30, CD33, Meso, HER1, Other Antigen Types

3) By Therapeutics Indications: Cancer, Autoimmune Diseases, Infectious Diseases, Others Therapeutics Indications

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Chimeric Antigen Receptor (CAR) T Cell Therapies: CD19-targeted CAR T Therapies, BCMA-targeted CAR T Therapies, CD22-targeted CAR T Therapies

2) By T Cell Receptor (TCR) Therapies: Neoantigen-targeted TCR Therapies, Viral Antigen-targeted TCR Therapies

3) By Other Product Types: Engineered T Cell Therapies, NK Cell Therapies

What Trends Are Redefining The Allogeneic T Cell Therapies Market Dynamics?

Major companies operating in the allogeneic T cell therapies market are dedicated to creating advanced chimeric antigen receptor (CAR) T-cell therapy initiatives to improve treatment outcomes and widen therapeutic possibilities. Innovative chimeric antigen receptor (CAR) T-cell therapy initiatives encompass sophisticated strategies aimed at boosting the effectiveness, accessibility, and delivery of CAR T-cell treatments for cancer. As an illustration, in October 2022, Allogene Therapeutics Inc., a US-based biotechnology company, launched CAR T Together, an inventive program intended to tackle difficulties in providing and accessing CAR T therapies. The program’s core objectives include simplifying enrollment in clinical trials and encouraging collaboration among oncologists to accelerate the advancement of allogeneic CAR T therapies. In contrast to autologous therapies, which are customized from a patient’s own cells, allogeneic therapies utilize T cells from healthy donors, which facilitates more efficient manufacturing processes.

Who Are The Top Performing Companies In The Allogeneic T Cell Therapies Market In Recent Years?

Major companies operating in the allogeneic t cell therapies market are Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc., Immatics NV, Sangamo Therapeutics Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Atara Biotherapeutics Inc., Sorrento Therapeutics Inc., Autolus Therapeutics Plc, MaxCyte Inc., Tessa Therapeutics Pte Ltd., Cell Medica Inc., Enlivex Therapeutics Ltd., Cellectis SA, Adaptimmune Therapeutics Plc, Medigene AG, Celyad Oncology SA, Allogene Therapeutics Inc., Bellicum Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/allogeneic-t-cell-therapies-global-market-report

What Regional Growth Trends Are Shaping The Allogeneic T Cell Therapies Market Outlook?

North America was the largest region in the allogeneic T cell therapies market in 2024. The regions covered in the allogeneic T cell therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Allogeneic T Cell Therapies Market Report:

https://www.thebusinessresearchcompany.com/customise?id=18952&type=smp

Browse Through More Reports Similar to the Global Allogeneic T Cell Therapies Market 2025, By The Business Research Company

Cells Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

Stem Cells Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/stem-cells-therapy-global-market-report

Cellulars Immunotherapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795